Valeant Pharmaceuticals International $4.565 Billion Term Loan Facility and $1.225 Billion Revolving Credit Facility

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) and Valeant Pharmaceuticals International in connection with a $4.565 billion senior secured term loan and $1.225 billion senior...

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here